| Issue Date | Title | Author(s) |
| 2019 | Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESCO trial. | Li, Jin; Qin, Shukui; Bai, Yuxian; Deng, Yanhong; Yang, Lei; Xu, Ruihua; Chen, Zhendong; Zhong, Haijun; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Yuan, Ying; Xu, Jianming; Shen, Lin; Wang, Ning; Zhu, Chao; Fan, Songhua; Gong, Wei; Wang, Wei |
| 20-May-2020 | Early carcinoembryonic antigen (CEA) dynamics to predict fruquintinib efficacy in FRESCO, a 3+line metastatic colorectal carcinoma (mCRC) phase III trial. | Bai, Yuxian; Qin, Shukui; Li, Jin; Deng, Yanhong; Yang, Lei; Xu, Rui-hua; Chen, Zhendong; Zhong, Haijun; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Yuan, Ying; Xu, Jianming; Shen, Lin; Wang, Ning; Zhang, Bin; Zhang, Qiang; Fan, Songhua; Guo, Xiaojun; Peng, Mengye |
| 2018 | Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial | Li, Jin; Qin, Shukui; Xu, Rui-Hua; Shen, Lin; Xu, Jianming; Bai, Yuxian; Yang, Lei; Deng, Yanhong; Chen, Zhen-dong; Zhong, Haijun; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Yuan, Ying; Zhou, Jianfeng; Xu, Nong; Liu, Tianshu; Ma, Dong; Wu, Changping; Cheng, Ying; Chen, Donghui; Li, Wei; Sun, Sanyuan; Yu, Zhuang; Cao, Peiguo; Chen, Haihui; Wang, Jiejun; Wang, Shubin; Wang, Hongbing; Fan, Songhua; Hua, Ye; Su, Weiguo |
| 10-Aug-2024 | Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy. | Zhang, Panpan; Lu, Ming; Shen, Lin; Song, Lijie; Zhang, Yanqiao; Chen, Zhendong; Cheng, Ying; Li, Zhiping; Zhang, Xing; Zhou, Jinghong; Shi, Haiyan; Tan, Panfeng; Fan, Songhua; Liu, Dingpan; Shi, Michael; Su, Weiguo |
| May-2024 | Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer | Zhang, Panpan; Chen, Zhendong; Shi, Si; Li, Zhiping; Ye, Feng; Song, Lijie; Zhang, Yanqiao; Yin, Fei; Zhang, Xing; Xu, Jianming; Cheng, Ying; Su, Weiguo; Shi, Michael; Fan, Songhua; Tan, Panfeng; Zhong, Chen; Lu, Ming; Shen, Lin |
| 20-May-2020 | Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors. | Bai, Chunmei; Xu, Jianming; Shen, Lin; Li, Jie; Zhou, Zhiwei; Chi, Yihebali; Li, Zhiping; Xu, Nong; Li, Enxiao; Liu, Tianshu; Bai, Yuxian; Yuan, Ying; Li, Xingya; Wang, Xiuwen; Chen, Jia; Ying, Jieer; Li, Jing; Fan, Songhua; Peng, Mengye; Su, Weiguo |
| Jul-2024 | Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors | Song, Yuqin; Cao, Junning; Zhang, Qingyuan; Li, Caixia; Qiu, Lugui; Qi, Junyuan; Zhang, Huilai; Li, Wenyu; Liu, Lihong; Jing, Hongmei; Zhou, Keshu; Zhang, Weijing; Zhang, Liling; Li, Daqi; Zou, Liqun; Yang, Haiyan; Qian, Wenbin; Zhou, Hui; Hu, Jianda; Yin, Hongyan; Fu, Sisi; Fan, Songhua; Xu, Qian; Wang, Jian; Jia, Xiaoyun; Dai, Guangxiu; Su, Weiguo; Zhu, Jun |
| Feb-2021 | Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in FRESCO trial | Qin, Shukui; Li, Jin; Bai, Yuxian; Deng, Yanhong; Yang, Lei; Xu, Rui-Hua; Zhong, Haijun; Chen, Zhendong; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Xu, Jianming; Peng, Cike; Chen, Yun; Li, Hongyan; Wang, Ning; Guo, Xiaojun; Peng, Mengye; Fan, Songhua; Shen, Lin |
| 2018 | Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in a phase II clinical trial. | Li, Jin; Xu, Ruihua; Bai, Yuxian; Xu, Jianming; Liu, Tianshu; Shen, Lin; Wang, Liwei; Pan, Hongming; Han, Rubing; Chen, Yun; Peng, Cike; Fan, Songhua; Hua, Ye |
| 2018 | Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in a phase II clinical trial. | Li, Jin; Xu, Ruihua; Bai, Yuxian; Xu, Jianming; Liu, Tianshu; Shen, Lin; Wang, Liwei; Pan, Hongming; Han, Rubing; Chen, Yun; Peng, Cike; Fan, Songhua; Hua, Ye |
| Sep-2020 | Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial | Li, Jin; Guo, Weijian; Bai, Yuxian; Deng, Yanhong; Yang, Lei; Chen, Zhendong; Zhong, Haijun; Xu, Ruihua; Pan, Hongming; Shu, Yongqian; Yuan, Ying; Zhou, Jianfeng; Xu, Nong; Liu, Tianshu; Ma, Dong; Wu, Changping; Cheng, Ying; Xu, Jianming; Chen, Donghui; Li, Wei; Sun, Sanyuan; Yu, Zhuang; Cao, Peiguo; Shen, Lin; Chen, Haihui; Wang, Shubin; Wang, Hongbing; Fan, Songhua; Guo, Xiaojun; Wang, Ning; Han, Rubing; Zhang, Bin; Qin, Shukui |
| Mar-2022 | Subgroup Analysis by Ki-67 and Baseline CgA of the Randomized, Placebo-Controlled Phase 3 Study of Surufatinib in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors (SANET-p) | Yu, Xianjun; Xu, Jianming; Shen, Lin; Bai, Chunmei; Li, Jie; Zhou, Zhiwei; Li, Zhiping; Li, Enxiao; Yuan, Xianglin; Chi, Yihebali; Yin, Yongmei; Lou, Wenhui; Xu, Nong; Bai, Yuxian; Zhang, Tao; Xiu, Dianrong; Wang, Xiuwen; Guan, Sha; Fan, Songhua; Su, Weiguo |
| Nov-2020 | Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study | Xu, Jianming; Shen, Lin; Zhou, Zhiwei; Li, Jie; Bai, Chunmei; Chi, Yihebali; Li, Zhiping; Xu, Nong; Li, Enxiao; Liu, Tianshu; Bai, Yuxian; Yuan, Ying; Li, Xingya; Wang, Xiuwen; Chen, Jia; Ying, Jieer; Yu, Xianjun; Qin, Shukui; Yuan, Xianglin; Zhang, Tao; Deng, Yanhong; Xiu, Dianrong; Cheng, Ying; Tao, Min; Jia, Ru; Wang, Wei; Li, Jing; Fan, Songhua; Peng, Mengye; Su, Weiguo |
